课题基金 / 基金详情

Does peripheral localized chronic inflammation predispose to neurodegeneration?

Does peripheral localized chronic inflammation predispose to neurodegeneration?
外周局部慢性炎症是否容易导致神经退行性变?
批准号:
7268114
负责人:
Stephanos Kyrkanides
金额:
$15.49万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-07-15 至 2008-12-31

项目摘要

项目成果

Stephanos Kyrkanides的其他基金

相关文献

中文摘要
翻译
描述(由申请人提供):本研究计划的目的是研究局部外周慢性炎症是否有助于体内神经炎症和最终神经退行性变的发展。为此,我们将在我们实验室最近开发的col1 - il -1 β - xat转基因小鼠模型中使用体细胞镶嵌分析,该模型利用基于Cre/loxP的分子遗传方法在时间和空间上激活含有休眠il -1 β转录单元的种系传播重组底物。初步数据显示,通过组织病理学、免疫组织化学和行为学研究评估,col1 - il - 1 β - xat转基因小鼠在关节内给予Cre后,膝关节和颞下颌关节发生关节炎。对外周诱导的col1 - il1 - β - xat转基因小鼠脑组织的分析显示,GFAP和MHC II类免疫细胞化学激活了星形胶质细胞和小胶质细胞,并上调了几种炎症相关基因的mRNA,包括小鼠IL-1、TNFalpha、MHC-II、GFAP和COX-2。提出以下具体目标,以进一步发展和表征该模型。(1)研究col1 - il - 1 β - xat转基因小鼠诱导膝关节关节炎后神经炎症的发展特征。(2)确定外周转基因激活是否影响复合col1 - il1 - β - xat /3xTg-AD转基因小鼠的脑病理。这些研究将确定局部外周炎症和衰老是否是小鼠神经炎症和阿尔茨海默病病理发展的危险因素。虽然在这里用于阿尔茨海默病的初步研究,但col1 - il - 1 β - xat小鼠可以立即应用于其他慢性神经退行性疾病的研究,如ALS、帕金森病和神经毒性疾病。最终,该模型将有助于阐明IL-1在脑炎症中的作用。这些信息对于我们理解抗炎治疗在AD和其他疾病中的益处至关重要,并将指导有针对性干预措施的合理应用和发展。
英文摘要
DESCRIPTION (provided by applicant): The purpose of this research proposal is to investigate whether localized peripheral chronic inflammation contributes to the development of neuroinflammation and ultimately neurodegeneration in vivo. To this end, we will employ somatic mosaic analysis in the Col1-IL1beta-XAT transgenic mouse model recently developed in our laboratory, which utilizes a Cre/loxP based molecular genetic method to temporally and spatially activate a germline-transmitted recombinational substrate containing a dormant IL-1beta transcription unit. Preliminary data demonstrate the development of arthritis in the knees and temporomandibular joints of Col1-IL1beta-XAT transgenic mice after intra-articular Cre administration as assessed by histopathological, immunohistochemical and behavioral studies. Analysis of brain tissue harvested from peripherally-induced Col1-IL1beta-XAT transgenic mice revealed astrocyte and microglia activation by GFAP and MHC class II immunocytochemistry, as well as mRNA upregulation of several inflammation-related genes, including murine IL-1, TNFalpha, MHC-II, GFAP and COX-2. The following specific aims are proposed to further develop and characterize this model. (1) Characterize the development of neuroinflammation following the induction of knee arthritis in young and old Col1-IL1beta-XAT transgenic mice over time. (2) Determine whether peripheral transgene activation impacts brain pathology in compound Col1-IL1beta-XAT/3xTg-AD transgenic mice. These studies will establish whether localized peripheral inflammation and aging are risk factors for the development of neuroinflammation and Alzheimer's disease pathology in mice. Although used here for a pilot investigation of Alzheimer's disease, the Col1-IL1beta-XAT mice can be immediately applied to studies of other chronic neurodegenerative conditions such as ALS, Parkinson's disease, and neurotoxic conditions. Ultimately, this model will contribute to the elucidation of the role of IL-1 in brain inflammation. Such information is critical to our understanding of the benefits of anti-inflammatory therapy in AD and other conditions and will guide the rational application and development of targeted interventions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Center for the Biologic Basis of Oral/Systemic Diseases (Phase III)
  • 批准号:
    9325021
  • 项目类别:
  • 资助金额:
    $105.2万
  • 财政年份:
    2014
  • 负责人:
    Stephanos Kyrkanides
  • 依托单位:
Does peripheral localized chronic inflammation predispose to neurodegeneration?
  • 批准号:
    7123579
  • 项目类别:
  • 资助金额:
    $15.99万
  • 财政年份:
    2006
  • 负责人:
    Stephanos Kyrkanides
  • 依托单位:
Recombinant FIV vectors for the delivery of siRNA therapy to joints
  • 批准号:
    7168687
  • 项目类别:
  • 资助金额:
    $20.33万
  • 财政年份:
    2006
  • 负责人:
    Stephanos Kyrkanides
  • 依托单位:
Joint degeneration: Somatic mosaic analysis in a transgenic mouse
  • 批准号:
    7136599
  • 项目类别:
  • 资助金额:
    $19.5万
  • 财政年份:
    2006
  • 负责人:
    Stephanos Kyrkanides
  • 依托单位: